> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Proposes New DTC Study on Risk Over-Warning
- URL: https://www.fdaweb.com/fda-proposes-new-dtc-study-on-risk-over-warning/
- Published: 2017-06-19T12:00:00.000Z
- Updated: 2026-09-14T22:30:03.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138960

*Federal Register* notice: FDA has proposed a new drug advertising study entitled “Experimental Study of Risk Information Amount and Location in Direct-to-Consumer Print Ads.” The study is intended to examine how repetition and over-warning apply to risk presentations in direct-to-consumer print advertising. The research aims to determine the downside to including the same warnings in both the main drug ad area and the brief summary. “Over-warning is the concept that individuals are exposed to so many warnings in the course of daily life that they are less likely to pay attention to any one particular warning,” the agency says in the notice. “In terms of presenting risk information, detailing too many risks may lead consumers to discount all risks, or miss the most important risk information. Similarly, habituation follows when readers see the same warning repeatedly.” FDA is asking for comments on the proposed research. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-06-19/pdf/2017-12600.pdf?ref=fdaweb.com).